Get the Stockscreener App
0.587
2.51%
-0.0151
After Hours:
.58
-0.007
-1.19%
Neurosense Therapeutics Ltd stock is traded at $0.587, with a volume of 85,150.
It is down -2.51% in the last 24 hours and down -22.50% over the past month.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
See More
Previous Close:
$0.6021
Open:
$0.62
24h Volume:
85,150
Relative Volume:
0.56
Market Cap:
$21.19M
Revenue:
-
Net Income/Loss:
$-10.21M
P/E Ratio:
-1.0048
EPS:
-0.5842
Net Cash Flow:
-
1W Performance:
-14.87%
1M Performance:
-22.50%
6M Performance:
-35.49%
1Y Performance:
-71.08%
1-Day Range:
$0.58
$0.6349
1-Week Range:
$0.58
$0.72
52-Week Range:
$0.58
$2.09
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Name
Neurosense Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare NRSN vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
0.587 | 21.74M | 0 | -10.21M | 0 | -0.5842 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Neurosense Therapeutics Ltd Stock (NRSN) Latest News
Neurosense Therapeutics Ltd - TradingKey
Neurosense Therapeutics Ltd (NRSN) Cash Flow - TradingKey
NRSN|Neurosense Therapeutics Ltd|Price:0.602|Chg%:-0.048 - TradingKey
Neurosense Therapeutics Ltd (NRSN) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
NeuroSense Moves PrimeC Toward Health Canada Drug Submission for ALS - TipRanks
NeuroSense Therapeutics (NASDAQ: NRSN) eyes Canada NDS for ALS drug - Stock Titan
NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS - PR Newswire
NeuroSense Therapeutics (NRSN) Slides 2.3% as Sellers Test Key Support at $0.66Calendar Spread Trade - dars.gov.et
NeuroSense Therapeutics (NRSN) Edges Higher as Key Support HoldsEquity Put Call - dars.gov.et
NeuroSense Therapeutics Ltd. (NRSN) Latest Stock News & Headlines - Yahoo Finance
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" - Nasdaq
Enterprise value to revenue forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSN - TradingView
Price to earnings forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSN - TradingView
NeuroSense Therapeutics Ltd. Warrant 2021-open end Financial Disclosures & SEC Filings - TradingView
NeuroSense bolsters case for multi-target Alzheimer’s strategy - Longevity.Technology
NRSN Q2 2025 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEarnings Revision Upgrade - dars.gov.et
NeuroDex ExoSORT Platform Demonstrates Treatment-Responsive Blood-Based Measurement of Neuronal TDP-43 in People Living with ALS - Bakersfield.com
NeuroSense (NRSN) Achieves Key Milestone in ALS Study - GuruFocus
NeuroSense Hits Key TDP-43 Endpoint in Phase 2b ALS Trial, Advances Toward Phase 3 - TipRanks
NeuroSense Says Phase 2b Trial of PrimeC in Amyotrophic Lateral Sclerosis Meets Primary Endpoint - marketscreener.com
NeuroSense (NRSN) Phase 2b ALS study cuts TDP-43, eyes Phase 3 - Stock Titan
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS - Nasdaq
NeuroSense reports positive Phase 2b ALS data - grafa.com
NeuroSense reports Phase 2 biomarker findings for PrimeC in Alzheimer’s disease - BioSpectrum Asia
Neurosense Therapeutics Ltd. Actuals & Estimates (NASDAQ:NRSN) - TradingView
Price to earnings forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
NRSN Forecast — Price Target — Prediction for 2027 - TradingView
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD - GuruFocus
Price to book forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
Number of shareholders of Neurosense Therapeutics Ltd. – FWB:H1Z - TradingView
NeuroSense Posts Positive Phase 2 Biomarker Signals for PrimeC in Alzheimer’s Trial - TipRanks
NeuroSense (NRSN) reports early Phase 2 PrimeC biomarker signals in Alzheimer’s - Stock Titan
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease - PR Newswire
Enterprise value to EBITDA forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
Number of shareholders of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
Price to sales forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
Enterprise value to EBIT forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
Enterprise value to revenue forward of NeuroSense Therapeutics Ltd. – NASDAQ:NRSNW - TradingView
EverythingALS to Host NeuroSense in a Community Event Named: PrimeCConnecting the Dots - The AI Journal
EverythingALS to Host NeuroSense in a Community Event Named: Pri - GuruFocus
ALS community event puts NeuroSense’s PrimeC data in focus June 24 - Stock Titan
NRSN Q1'26 Earnings: EPS estimate is (0.08) USD - TradingView
Neurosense Therapeutics Ltd (NRSN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neurosense Therapeutics Ltd (NRSN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Institutional Confidence - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Neurosense Therapeutics Ltd (NRSNW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Neurosense Therapeutics Ltd Stock (NRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):